TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
TransMedics (Nasdaq:TMDX) will release its second quarter 2026 financial results after market close on Tuesday, August 4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransMedics (Nasdaq:TMDX) will release its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Management will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT with phone and webcast access for investors.
Details
News Market Reaction – TMDX
On Jul 22, the first trading day after this news, TMDX closed 4.16% below the previous close. Our momentum scanner recorded 3 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 22 session.
Key Figures
- Reporting period
- Second quarter 2026
- Financial results scheduled for release
- Results release date
- August 4, 2026
- After market close
- Conference call time
- 4:30 p.m. ET
- Corresponding results conference call
- Conference call time
- 1:30 p.m. PT
- Corresponding results conference call
Previous Earnings date Reports
-
Announced first-quarter 2026 results release date and conference call schedule.
-
Announced fourth-quarter and full-year 2025 results release date and call schedule.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 6054544. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
Gilmartin Group
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-second-quarter-2026-financial-results-on-august-4-2026-302831235.html
SOURCE TransMedics Group, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.